Trialscagrisemacagrilintidesemaglutidenovo nordiskobesity

Novo Nordisk CagriSema Phase 3 obesity trial listed as active, not recruiting

The registration covers a randomized comparison of CagriSema 2.4 mg/2.4 mg against cagrilintide, semaglutide and placebo, followed by a two-year off-treatment extension.

By Priya Raman · Science Reporter

Sep 30 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT05567796, sponsored by Novo Nordisk and started November 2022, randomizes participants with overweight or obesity to weekly CagriSema, cagrilintide, semaglutide or placebo for about 18 months.
02An extension will track body weight and weight-related disease for two years after participants stop study medicine, a design point relevant to clinicians facing post-discontinuation regain.
03The listing is a registry record, not a results readout; status is active, not recruiting, and no outcome data are reported.

From the source

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796 · PHASE3 · ACTIVE NOT RECRUITING · Sponsor: Novo Nordisk A/S · Conditions: Obesity.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT05567796